DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Felvizumab
Felvizumab
Inclusion and Exclusion Criteria for Each Key Question
(12) United States Patent (10) Patent No.: US 9.468,689 B2 Zeng Et Al
Anticuerpos Monoclonales: Desarrollo Físico Y Perspectivas Terapéuticas
WO 2015/028850 Al 5 March 2015 (05.03.2015) P O P C T
Phage Display-Based Strategies for Cloning and Optimization of Monoclonal Antibodies Directed Against Human Pathogens
Pharmaceutical Appendix to the Tariff Schedule 2
Monoclonal Antibodies Present New Opportunities in Disease Diagnosis and Treatment, Asian Journal of Pharmaceutical Technology & Innovation, 04 (19); 2016, 51-60
Pharmaceutical Appendix to the Tariff Schedule 2
WO 2016/176089 Al 3 November 2016 (03.11.2016) P O P C T
(INN) for Biological and Biotechnological Substances
Humanized Antibody
INN Working Document 05.179 Update 2011
Stembook 2018.Pdf
A1446-Anti-RSV (Felvizumab)
IUPAC Glossary of Terms Used in Immunotoxicology (IUPAC Recommendations 2012)*
WO 2017/176762 Al 12 October 2017 (12.10.2017) P O P C T
International Nonproprietary Names (Inn) for Biological and Biotechnological Substances
(INN) for Biological and Biotechnological Substances
Top View
Anti-RSV [RSHZ19 (Felvizumab)] Standard Size, 200 Μg, Ab00729-23.0 View Online
(12) United States Patent (10) Patent No.: US 9,446,134 B2 Maggio (45) Date of Patent: *Sep
Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes
Customs Tariff - Schedule
Wo 2010/095940 A2
Antibody-Drug Analogues
Anti-RSV [RSHZ19 (Felvizumab)] Standard Size Ab00729-2.0
Anti-C1S (Sutimlimab), Humanized Antibody
Customs Tariff - Schedule Xxi - 1
Anti-RSV [RSHZ19 (Felvizumab)] Standard Size Ab00729-19.0
Produktinformation
Harmonized Tariff Schedule of the United States (2006) (Rev
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
Anti-RSV [RSHZ19 (Felvizumab)] Standard Size Ab00729-10.0
Pharmaceutical Appendix to the Tariff Schedule 2
(INN) for Biological and Biotechnological Substances
Anticorps Monoclonaux En Infectiologie Des Nouveaux Partenaires Dans L'arsenal Thérapeutique
Pharmaceuticals Appendix
Assessment of the Evolution of Cancer Treatment Therapies
Supplemental Table 1: Inclusion and Exclusion Criteria
Antiviral Activity of the Medicinal Plants, Adina Pilulifera, Narcissus
INN-Nimet 1 20.8.2019 a Abacavir Abacavirum Abakaviiri